Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug could stop knee infections after replacement

NCT ID NCT07214311

Disease control Sponsor: Peptilogics Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 18, 2026 · Updated 13 times

Summary

This study tests whether an investigational drug called PLG0206 can prevent infections from coming back after knee replacement surgery. About 240 adults who need a special cleaning surgery (DAIR) for an infected knee joint will receive either PLG0206 or a placebo during the procedure. Researchers will track them for one year to see if the drug reduces the need for further surgeries or other treatments.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PLG0206 (an investigational drug used as an irrigation solution during surgery)
What this could lead to
If it works, this could provide a new way to prevent repeat infections after knee replacement surgery, reducing the need for additional surgeries.
What could go wrong
This is an early-to-mid-stage trial with only 240 participants, so results may not apply to everyone. The drug is still experimental, and its safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2/3

Runs two stages together: whether the treatment works, then large-scale confirmation.

Participants

About 240 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participants age between 18 and \<86 years * Able to provide informed consent, geographically stable, and able to comply with the required follow-up visits * Suspected or confirmed PJI of the knee * Well-fixed and positioned prosthesis and good condition of surrounding soft tissue (no sinus tract) * A single DAIR procedure is indicated as treatment of PJI * Agree to use contraceptives if of childbearing potential Exclusion Criteria: * Loose prosthesis or surgical treatment planned for removal of well-fixed, nonmodular implants * Anticipated to require antibiotic therapy for \>6 months after DAIR procedure * Infection spread beyond the affected knee joint (e.g., osteomyelitis) * History of a prior confirmed PJI of the affected knee, including prior DAIR or revision surgery for PJI * Two or more prior revisions in the affected joint for reasons other than infection * Epithelialized sinus tract with evidence of communication to the joint or visualization of prosthesis * Diabetes mellitus and with an A1c ≥9% within 3 months, according to medical history * History of malignant disease and having received immunosuppressive therapy, radiation therapy, or chemotherapy within the past year * Known immunodeficiency (e.g., splenectomy; sickle cell anemia; human immunodeficiency virus \[HIV\] with recent CD4 count \<200 cells/mm3; or primary humoral, bone marrow, or other transplantation)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Periprosthetic joint infection following total knee arthroplasty are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

periprosthetic joint infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prosthetic-joint infection

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    18 sites in 2 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Clinical Trial Site

    RECRUITING

    Sarasota, Florida, 34239, United States

  • Clinical Trial Site

    RECRUITING

    Tamarac, Florida, 33321, United States

  • Clinical Trial Site

    RECRUITING

    Shreveport, Louisiana, 71103, United States

  • Clinical Trial Site

    RECRUITING

    Baltimore, Maryland, 21215, United States

  • Clinical Trial Site

    RECRUITING

    Boston, Massachusetts, 02120, United States

  • Clinical Trial Site

    WITHDRAWN

    New York, New York, 10032, United States

  • Clinical Trial Site

    RECRUITING

    Leland, North Carolina, 28451, United States

  • Clinical Trial Site

    RECRUITING

    Cincinnati, Ohio, 45267, United States

  • Clinical Trial Site

    RECRUITING

    Cleveland, Ohio, 44195, United States

  • Clinical Trial Site

    RECRUITING

    Columbus, Ohio, 43210, United States

  • Clinical Trial Site

    RECRUITING

    Pittsburgh, Pennsylvania, 15232, United States

  • Clinical Trial Site

    RECRUITING

    Dallas, Texas, 75390, United States

  • Clinical Trial Site

    RECRUITING

    Edinburg, Texas, 78539, United States

  • Clinical Trial Site

    RECRUITING

    Salt Lake City, Utah, 84132, United States

  • Clinical Trial Site

    RECRUITING

    Morgantown, West Virginia, 26506, United States

  • Clinical Trial Site

    RECRUITING

    Cambridge, Cambridgeshire, CB2 0QQ, United Kingdom

  • Clinical Trial Site

    RECRUITING

    Edinburgh, Lothian, EH16 4SA, United Kingdom

  • Clinical Trial Site

    NOT_YET_RECRUITING

    Norwich, Norfolk, NR4 7UY, United Kingdom

  • Clinical Trial Site

    RECRUITING

    Leeds, West Yorkshire, LS7 4SA, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.